특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models vi

작성자
관리자
작성일
2024-02-01 22:01
조회
230

Lim SH, Yoon HY, Park SJ, Song S, Shim MK, Yang S, Kang SW, Lim DK, Kim BS, Moon SH*, Kim KM*. Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography. Biomaterials.2021 Jan;266:120472.


Abstract


Human embryonic stem cells-derived endothelial progenitor cells (hEPCs) were utilized as cell therapeutics for the treatment of ischemic diseases. However, in vivo tracking of hEPCs for predicting their therapeutic efficacy is very difficult. Herein, we developed bioorthogonal labeling strategy of hEPCs that could non-invasively track them after transplantation in hind limb ischemia models. First, hEPCs were treated with tetraacylated N-azidomannosamine (Ac4ManNAz) for generating unnatural azide groups on the hEPCs surface. Second, near-infrared fluorescence (NIRF) dye, Cy5, conjugated dibenzocylooctyne (DBCO-Cy5) was chemically conjugated to the azide groups on the hEPC surface via copper-free click chemistry, resulting Cy5-hEPCs. The bioorthogonally labeled Cy5-hEPCs showed strong NIRF signal without cytotoxicity and functional perturbation in tubular formation, oxygen consumption and paracrine effect of hEPCs in vitro. In hind limb ischemia models, the distribution and migration of transplanted Cy5-hEPCs were successfully monitored via fluorescence molecular tomography (FMT) for 28 days. Notably, blood reperfusion and therapeutic neovascularization effects were significantly correlated with the initial transplantation forms of Cy5-hEPCs such as ‘condensed round shape’ and ‘spread shape’ in the ischemic lesion. The condensed transplanted Cy5-hEPCs substantially increased the therapeutic efficacy of hind limb ischemia, compared to that of spread Cy5-hEPCs. Therefore, our new stem cell labeling strategy can be used to predict therapeutic efficacy in hind limb ischemia and it can be applied a potential application in developing cell therapeutics for regenerative medicine.



논문확인(클릭시 이동) 
전체 52
번호 제목 작성자 작성일 추천 조회
42
Multiple isogenic GNE-myopathy modeling with mutation specific phenotypes from human pluripotent stem cells by base editors.
관리자 | 2024.02.02 | 추천 0 | 조회 233
관리자 2024.02.02 0 233
41
In silico design and fabrication of an SFI chip-based microspheroid culture system.
관리자 | 2024.02.02 | 추천 0 | 조회 291
관리자 2024.02.02 0 291
40
Effect and application of cryopreserved three-dimensional microcardiac spheroids in myocardial infarction therapy
관리자 | 2024.02.01 | 추천 0 | 조회 233
관리자 2024.02.01 0 233
39
Blue laser-induced selective vasorelaxation by the activation of NOSs.
관리자 | 2024.02.01 | 추천 0 | 조회 242
관리자 2024.02.01 0 242
38
Therapeutic Efficacy of Artificial Skin Produced by 3D Bioprinting.
관리자 | 2024.02.01 | 추천 0 | 조회 268
관리자 2024.02.01 0 268
37
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization  international pharmacov
관리자 | 2024.02.01 | 추천 0 | 조회 239
관리자 2024.02.01 0 239
36
Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models vi
관리자 | 2024.02.01 | 추천 0 | 조회 230
관리자 2024.02.01 0 230
35
Application of co-culture technology of epithelial type cells and mesenchymal type cells using nanopatterned structures
관리자 | 2024.02.01 | 추천 0 | 조회 265
관리자 2024.02.01 0 265
34
Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivat
관리자 | 2024.02.01 | 추천 0 | 조회 289
관리자 2024.02.01 0 289
33
Antiviral activity and safety of remdesivir against SARS-CoV- 2 infection in human pluripotent stem cell-derived cardiomyocytes
관리자 | 2024.02.01 | 추천 0 | 조회 250
관리자 2024.02.01 0 250